KASL Consensus Statement for Pharmacologic Treatment of Metabolic Dysfunction-Associated Steatohepatitis: Focus on Semaglutide

Metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis (MASH) impose a rapidly increasing hepatic and cardiometabolic burden worldwide and in Korea. Following the phase 3 ESSENCE trial, which demonstrated the histological efficacy of semaglutide in noncirrhotic MASH with fibrosis, practical guidance for routine clinical care is needed. The Korean Association for the Study of the Liver developed this expert consensus statement on semaglutide treatment in MASH. Using the RAND/UCLA Appropriateness Method, a 15-member expert panel rated 98 clinical scenarios covering patient selection, dosing, response assessment, adverse event management, and metabolic comorbidities over two rating rounds with a structured panel discussion. Semaglutide is primarily intended for patients with noncirrhotic MASH and stage 2-3 fibrosis. Eligibility should be assessed using a two-step strategy of age-adjusted Fibrosis-4 index screening followed by vibration-controlled transient elastography (VCTE). A VCTE-derived liver stiffness measurement (LSM) of 10-15 kPa defines the preferred treatment range; 15-20 kPa is acceptable when cirrhosis and portal hypertension are excluded, whereas 8-10 kPa requires repeat VCTE, magnetic resonance elastography (eligible range, 3.1-4.4 kPa), or liver biopsy. Semaglutide is initiated at 0.25 mg once weekly and escalated every 4 weeks to a target maintenance dose of 2.4 mg. Response should be assessed with noninvasive tests after at least 18 months; a ≥30% reduction in VCTE-derived LSM suggests response. This consensus provides a structured framework for semaglutide use in MASH, integrated with management of obesity, type 2 diabetes, cardiovascular risk, and chronic kidney disease.

Authors

Institutions

Publication Details

Journal
Clinical and Molecular Hepatology
Published
2026-11-17
DOI
https://doi.org/10.3350/cmh.2026.1329
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

KASL Consensus Statement for Pharmacologic Treatment of Metabolic Dysfunction-Associated Steatohepatitis: Focus on Semaglutide

Jung Hee Kim, Dae Won Jun, Byoung Kuk Jang, Gwang Hyeon Choi et al.
6 links
Clinical and Molecular Hepatology
Liver Disease Diagnosis and Treatment
article

KASL Consensus Statement for Pharmacologic Treatment of Metabolic Dysfunction-Associated Steatohepatitis: Focus on Semaglutide

Jung Hee Kim, Dae Won Jun, Byoung Kuk Jang, Gwang Hyeon Choi, Won Sohn, Ji Hoon Seo, Jin‐Woo Lee, Sang Hoon Park, Young Chang, Young Suk Lim, Jae Seung Lee, Yoon Jun Kim, Yong Kyun Cho, Soo Jong Yu, Seung Up Kim, Miyoung Choi, Bo Hyun Kim, Young-Sun Lee, Won Kim
article en

Abstract

Metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis (MASH) impose a rapidly increasing hepatic and cardiometabolic burden worldwide and in Korea. Following the phase 3 ESSENCE trial, which demonstrated the histological efficacy of semaglutide in noncirrhotic MASH with fibrosis, practical guidance for routine clinical care is needed. The Korean Association for the Study of the Liver developed this expert consensus statement on semaglutide treatment in MASH. Using the RAND/UCLA Appropriateness Method, a 15-member expert panel rated 98 clinical scenarios covering patient selection, dosing, response assessment, adverse event management, and metabolic comorbidities over two rating rounds with a structured panel discussion. Semaglutide is primarily intended for patients with noncirrhotic MASH and stage 2-3 fibrosis. Eligibility should be assessed using a two-step strategy of age-adjusted Fibrosis-4 index screening followed by vibration-controlled transient elastography (VCTE). A VCTE-derived liver stiffness measurement (LSM) of 10-15 kPa defines the preferred treatment range; 15-20 kPa is acceptable when cirrhosis and portal hypertension are excluded, whereas 8-10 kPa requires repeat VCTE, magnetic resonance elastography (eligible range, 3.1-4.4 kPa), or liver biopsy. Semaglutide is initiated at 0.25 mg once weekly and escalated every 4 weeks to a target maintenance dose of 2.4 mg. Response should be assessed with noninvasive tests after at least 18 months; a ≥30% reduction in VCTE-derived LSM suggests response. This consensus provides a structured framework for semaglutide use in MASH, integrated with management of obesity, type 2 diabetes, cardiovascular risk, and chronic kidney disease.

Clinical and Molecular Hepatology
Seoul National University (KR), Inha University (KR), Yonsei University (KR), Soonchunhyang University (KR), Severance Hospital (KR), Korea University Medical Center (KR), Seoul Metropolitan Government (KR), Soonchunhyang University Hospital Seoul (KR), Asan Medical Center (KR), Seoul National University Hospital (KR), Seoul National University Bundang Hospital (KR), University of Ulsan (KR), Hallym University Kangnam Sacred Heart Hospital (KR), SNUH SMG-SNU Boramae Medical Center (KR), Kangbuk Samsung Hospital (KR), National Cancer Center (KR), Hanyang University Seoul Hospital (KR), National Evidenc- based healthcare Collaborating Agency (KR), Inha University Hospital (KR), Korea University (JP), Korea University Guro Hospital (KR), Keimyung University Dongsan Hospital (KR), Hanyang University (KR), Keimyung University (KR), Sungkyunkwan University (KR)
Good health and well-being
Liver Disease Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon